Fig. 4

Resting state of the sensorimotor network as shown by the resting state functional MRI (rsfMRI) for Cerebrolysin (30 ml/day; a1) and placebo (a2) in the affected (AH) and unaffected (UH) hemispheres at baseline (Day 8, T0), immediately after treatment (Day 29, T1) and three (Day 90, T3) months after stroke onset. Analysis was based on the intention-to-treat (ITT) population using the last observation carried forward (LOCF) approach for missing data in the subgroup of patients with severe motor impairment (FMA <50) from 29 patients (Cerebrolysin n = 13, placebo n = 16). Time course (b1) and changes from baseline (b2) are given for the lateralization index. *p < 0.05 between time points in each group